STERIS Expects FY25 As Reported Revenue From Continuing Operations To Increase 6.5%-7.5%; Adjusted EPS From Continuing Operations Of $9.05 - $9.25 (Est $9.33)
STERIS Expects FY25 As Reported Revenue From Continuing Operations To Increase 6.5%-7.5%; Adjusted EPS From Continuing Operations Of $9.05 - $9.25 (Est $9.33)
STERIS預計，25財年持續經營業務的列報收入將增長6.5％-7.5％；調整後的持續經營每股收益爲9.05美元至9.25美元（約合9.33美元）
Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.
資本支出預計約爲3.6億美元，自由現金流預計約爲7億美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。